DJ Sartorius Stedim Biotech releases Universal Registration Document 2024
Sartorius Stedim Biotech SA / Key word(s): Annual Results
Sartorius Stedim Biotech releases Universal Registration Document 2024
17-Feb-2025 / 10:02 CET/CEST
=----------------------------------------------------------------------------------------------------------------------
Aubagne, France | February 17, 2025
Sartorius Stedim Biotech releases Universal Registration Document 2024
Sartorius Stedim Biotech, a leading partner of the biopharma industry, today released its Universal Registration
Document 2024 including the Annual Financial Report. The document is available at the following link: https://
ir-reports.sartorius.com/en/ssb/fy-2024/
Financial calendar
March 25, 2025 Annual Shareholders' Meeting
April 16, 2025 Publication of the first quarter results January to March 2025
July 22, 2025 Publication of the half-year results January to June 2025
October 16, 2025 Publication of the nine-month results January to September 2025
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of
innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications,
such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are
quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales
entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through
acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros.
Currently, more than 9,900 employees are working for customers around the globe.
Visit our Newsroom and follow us on LinkedIn.
Contact
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com
=----------------------------------------------------------------------------------------------------------------------
Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Language: English
Issuer: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
EQS News ID: 2086777
End of Announcement - EQS News Service
=------------------------------------------------------------------------------------
2086777 17-Feb-2025 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2086777&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face
(END) Dow Jones Newswires
February 17, 2025 04:02 ET (09:02 GMT)
© 2025 Dow Jones News
